Cargando…
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
BACKGROUND: Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation. METHODS: We searched for mutations in the ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 a...
Autores principales: | Rocquain, Julien, Carbuccia, Nadine, Trouplin, Virginie, Raynaud, Stéphane, Murati, Anne, Nezri, Meyer, Tadrist, Zoulika, Olschwang, Sylviane, Vey, Norbert, Birnbaum, Daniel, Gelsi-Boyer, Véronique, Mozziconacci, Marie-Joelle |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923633/ https://www.ncbi.nlm.nih.gov/pubmed/20678218 http://dx.doi.org/10.1186/1471-2407-10-401 |
Ejemplares similares
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010) -
TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017) -
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2012) -
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021) -
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)